Home » Stocks » VTRS

Viatris, Inc. (VTRS)

Stock Price: $17.43 USD 0.12 (0.69%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $17.40 -0.03 (-0.17%) Jan 22, 7:54 PM
Market Cap 20.83B
Revenue (ttm) 11.51B
Net Income (ttm) 266.40M
Shares Out 516.90M
EPS (ttm) 0.52
PE Ratio 33.52
Forward PE 4.39
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $17.43
Previous Close $17.31
Change ($) 0.12
Change (%) 0.69%
Day's Open 17.20
Day's Range 17.10 - 17.52
Day's Volume 5,726,564
52-Week Range 16.19 - 18.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

High dividend yields plus low valuations could be just the ticket for income-seeking investors.

Other stocks mentioned: ABBV, BMY
Seeking Alpha - 1 week ago

I received shares in Viatris following the spin-off from Pfizer. The company will only start paying a dividend next year.

The Motley Fool - 1 week ago

It's no bull: These stocks are set to weather a potential storm.

Other stocks mentioned: BEP, DG
Seeking Alpha - 2 weeks ago

Growing your dividend income takes time and consistency. In December, we (my wife and I) received a total of $5,483.32 of dividend income.

Other stocks mentioned: AFL, BLK, DFS, KEY, LMT, NWFL, O, PFE, T, TGT, VYM
The Motley Fool - 4 weeks ago

All three also offer attractive dividends.

Other stocks mentioned: ABBV, BMY
The Motley Fool - 1 month ago

Whether or not you believe that Viatris can make you rich depends on how strongly you believe in biosimilars.

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ALXO, ATH, BH, GDYN, LXRX, SNEX, SONA, UEPS, UHAL
PRNewsWire - 1 month ago

PITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the l...

PRNewsWire - 1 month ago

PITTSBURGH, Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation ("TRC") to purchase up to 6,000,000 sha...

Zacks Investment Research - 1 month ago

Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.

Market Watch - 1 month ago

Shares of Viatris Inc. were down 0.2% in premarket trading on Friday after the company said it plans to close or divest up to 15 manufacturing sites and may cut up to 9,000 jobs, or 20% of its...

PRNewsWire - 1 month ago

PITTSBURGH, Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global restructuring initiative. The restructuri...

About VTRS

Viatris, a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. Its portfolio comprises approximately 1,400 approved molecules across a range of therapeutic areas, including non-communicable and infectious diseases; complex generic and branded medicines; a portfolio of biosimilars; and various over-the-counter consumer products, as well as active pharmaceutical ingredients. The company is headquartered in Canonsburg, Pennsylvania.

Industry
Drug Manufacturers-Specialty & Generic
Stock Exchange
NASDAQ
Ticker Symbol
VTRS
Full Company Profile

Financial Performance

In 2019, Viatris's revenue was $11.50 billion, an increase of 0.58% compared to the previous year's $11.43 billion. Earnings were $16.80 million, a decrease of -95.23%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Viatris is 21.88, which is an increase of 25.53% from the latest price.

Price Target
$21.88
(25.53% upside)